ARPO To Report Glaucoma Trial Data In Q4, ARDX To Face FDA In April, PFE's Pipeline Update

Today's Daily Dose brings you news about Aerpio Pharma's clinical trial catalyst, Adicet Bio's reverse merger with resTORbio, FDA decision date of Ardelyx's Tenapanor, Cel-Sci's phase III study of Multikine for the treatment of newly diagnosed head and neck cancer, and an update on Pfizer's pipeline.

from RTT - Biotech https://ift.tt/3c3LtOo
via IFTTT